Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BACLOFEN vs IPLEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.
IPLEX (mecasermin rinfabate) is a complex of recombinant human insulin-like growth factor-1 (IGF-1) and its binding protein (IGFBP-3). It activates the IGF-1 receptor, promoting linear growth by stimulating chondrocyte proliferation in epiphyseal growth plates, as well as exerting anabolic effects on muscle and other tissues.
Spasticity due to multiple sclerosis (FDA approved),Spinal cord injury (FDA approved),Intrathecal use for severe spasticity of cerebral origin (off-label),Hiccups (off-label),Alcohol withdrawal syndrome (off-label),Trigeminal neuralgia (off-label)
FDA: Treatment of growth failure in children with severe primary IGF-1 deficiency (e.g., Laron syndrome, GH gene deletion, GH receptor defects) or with neutralizing antibodies to GH.,Off-label: Treatment of insulin-like growth factor-1 deficiency in adults; investigational in ALS and other neurodegenerative disorders.
Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.
0.5-2 mg/kg subcutaneously once daily, titrated based on IGF-I levels.
Terminal half-life: 2.5-4 hours (young adults), 4-8 hours (elderly); clinical context: requires frequent dosing for spasticity.
Terminal elimination half-life of 10-12 hours after subcutaneous administration, supporting twice-daily dosing.
Metabolized via hepatic deamination by transaminase; primarily excreted unchanged in urine (approximately 70-80%), with minor hepatic metabolism.
Mecasermin (IGF-1) is metabolized by proteolytic degradation into amino acids; IGFBP-3 is also proteolytically degraded. No significant cytochrome P450 metabolism.
Renal: 70-80% unchanged; fecal: <5%; biliary: minimal.
Renal excretion of intact IGF-I and its metabolites; approximately 70% eliminated via kidneys, with 30% biliary/fecal.
30-35% bound to albumin.
Approximately 90% bound to IGF-binding proteins (IGFBPs), primarily IGFBP-3, and a minor fraction to albumin.
Vd: 0.5-0.7 L/kg; indicates distribution into total body water.
Vd approximately 0.25-0.30 L/kg, indicating distribution primarily to extracellular fluid and well-perfused tissues.
Oral: 70-85% with high variability; intrathecal: 100%.
Subcutaneous: Approximately 80-100%.
Cr Cl 30-50 m L/min: reduce dose by 50%; Cr Cl <30 m L/min: avoid use or use with extreme caution, reduce dose by 75%.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For moderate impairment (Cr Cl 30–50 m L/min), reduce dose by 25%; monitor IGF-I closely.
No specific guidelines; use with caution due to potential for increased sedation/neurotoxicity.
Not studied in hepatic impairment; use with caution in Child-Pugh B or C; consider dose reduction based on clinical response and IGF-I monitoring.
Children 2-7 years: initial 2.5 mg orally 4 times daily, increase by 2.5 mg/dose every 3 days to max 40 mg/day; children ≥8 years: initial 5 mg orally 3 times daily, increase as in adults to max 60 mg/day.
0.5-2 mg/kg subcutaneously once daily, titrated to achieve age-appropriate IGF-I levels.
Start at low end of dosing range (5 mg twice daily), titrate slowly due to increased risk of sedation, weakness, and cognitive impairment.
No specific dose adjustment; initiate at lower end of dosing range (0.5 mg/kg/day) due to potential for decreased renal function and increased sensitivity.
Abrupt discontinuation may cause withdrawal symptoms including hallucinations, seizures, and life-threatening hyperpyrexia; taper dose gradually.
Not available (no FDA boxed warning as of current labeling).
May cause CNS depression (drowsiness, sedation) and impair ability to drive or operate machinery.,Risk of withdrawal syndrome including fever, altered mental status, and autonomic instability upon abrupt cessation.,Use with caution in patients with renal impairment; dose adjustment required.,May exacerbate psychiatric disorders; monitor for hallucinations, confusion.,Risk of respiratory depression when combined with other CNS depressants.
Hypoglycemia (especially in fasted state), intracranial hypertension, slipped capital femoral epiphysis, lymphatic tissue hypertrophy (e.g., tonsillar/adenoid enlargement), allergic reactions, and progression of pre-existing malignancies. Injection site reactions, lipohypertrophy. Risk of hyperglycemia if used in patients with diabetes. Monitor blood glucose, fundoscopy for papilledema, and for signs of hip/knee pain.
Hypersensitivity to baclofen.,Intrathecal formulation is contraindicated in patients with active infection or bleeding disorders at lumbar puncture site.,Women who are breastfeeding (relative contraindication).
Hypersensitivity to mecasermin rinfabate or any component; active or suspected neoplasia; epiphyseal closure (skeletal maturity); children with closed epiphyses (except if indicated for severe IGF-1 deficiency with open epiphyses).
No specific food interactions. Avoid alcohol due to additive CNS depression.
No specific food interactions reported. However, to minimize hypoglycemia risk, IPLEX should be administered immediately after a meal or snack. Avoid prolonged fasting. Alcohol use may increase hypoglycemia risk; avoid or limit alcohol consumption.
First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third trimesters: Risk of neonatal withdrawal (hypertonia, seizures) with chronic maternal use. Avoid unless benefit outweighs risk.
IPLEX (mecasermin rinfabate) is a recombinant human insulin-like growth factor-1 (IGF-1) complexed with IGF-binding protein-3. There are no adequate and well-controlled studies in pregnant women. In animal studies, administration of IGF-1 during organogenesis resulted in fetal growth retardation and increased skeletal abnormalities at doses similar to human exposure. Due to its growth-promoting effects, potential for teratogenicity, and interference with normal fetal development, IPLEX is contraindicated during pregnancy. First trimester: Risk of skeletal and growth abnormalities. Second and third trimesters: continued risk of abnormal fetal growth and development, including organ overgrowth or underdevelopment. Use only if maternal benefits outweigh potential fetal risks; however, generally avoided.
Baclofen excreted into breast milk in low concentrations (M/P ratio approximately 0.43). Relative infant dose estimated 0.9% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but monitor infant for sedation and hypotonia.
It is unknown whether mecasermin rinfabate or its components (IGF-1, IGFBP-3) are excreted in human milk. Due to the potential for serious adverse reactions in the nursing infant, including growth stimulation and hypoglycemia, breast-feeding is not recommended during IPLEX therapy. No M/P ratio is available.
No specific dose adjustments recommended. Increased renal blood flow and GFR in pregnancy may reduce baclofen levels; monitor clinical effect and adjust dose as needed. Avoid abrupt discontinuation due to risk of maternal withdrawal and rebound spasticity.
No specific pharmacokinetic studies of IPLEX in pregnancy are available. The physiological changes of pregnancy (increased plasma volume, altered renal function, increased hepatic metabolism) may affect clearance of mecasermin rinfabate; however, due to its contraindication, dose adjustments during pregnancy are not recommended. If absolutely necessary, use the lowest effective dose and monitor for efficacy and adverse effects. No established dose adjustment guidelines exist.
Abrupt withdrawal can cause severe rebound spasticity, fever, and rhabdomyolysis; taper by 5-10 mg/week. Intrathecal baclofen pumps require careful monitoring for overdose (respiratory depression) or withdrawal. Use with caution in renal impairment (dose adjust for Cr Cl <30 m L/min).
IPLEX (mecasermin rinfabate) is a complex of recombinant human insulin-like growth factor-1 (rh IGF-1) and its binding protein (rh IGFBP-3). It is indicated for growth failure in children with severe primary IGF-1 deficiency (e.g., Laron syndrome) or with GH gene deletion who have developed neutralizing antibodies to GH. Administer subcutaneously; dose is based on IGF-1 levels. Monitor for hypoglycemia, especially after injection; patients should eat shortly after dosing. Do not use in patients with closed epiphyses or active neoplasia. May cause lymphoproliferative disorders; monitor for splenomegaly, lymphadenopathy.
Do not stop taking baclofen suddenly; sudden discontinuation can cause serious withdrawal symptoms including hallucinations, seizures, and high fever.,Avoid alcohol and CNS depressants as they increase sedation and risk of falls.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Take exactly as prescribed; missed doses can lead to muscle spasms or withdrawal.,Report any unusual muscle stiffness, rapid heart rate, or dark urine immediately.
Inject IPLEX within 20 minutes after a meal or snack to prevent hypoglycemia.,Rotate injection sites (abdomen, thigh, upper arm) to avoid lipohypertrophy.,Report symptoms of hypoglycemia (shakiness, sweating, confusion) or increased growth velocity.,Keep a log of blood glucose levels if advised by your doctor.,Store IPLEX in the refrigerator (2-8°C); do not freeze. Protect from light.,Do not share needles or pens; dispose of used needles in a sharps container.,Continue regular follow-up appointments for growth monitoring and blood tests.
"Sevoflurane enhances the inhibitory effects of baclofen on the central nervous system by potentiating GABA-B receptor activity, leading to an increased risk of profound sedation, respiratory depression, and hypotension. This synergistic interaction can result in prolonged recovery from anesthesia and the need for ventilatory support. Clinically, patients may exhibit exaggerated muscle relaxation and a delayed emergence from anesthesia, particularly at higher doses of either agent."
"Concomitant use of etidocaine, an amide-type local anesthetic that blocks voltage-gated sodium channels, and baclofen, a GABAB receptor agonist used for muscle spasticity, may lead to additive central nervous system (CNS) depression and respiratory depression. This interaction results from synergistic depressant effects on the brainstem and spinal cord, increasing the risk of sedation, dizziness, ataxia, and impaired consciousness. Clinically, patients may experience excessive drowsiness, respiratory compromise, and impaired motor coordination, particularly in the elderly or those with pre-existing renal impairment where baclofen accumulation is more likely."
"The coadministration of Baclofen and Metaxalone results in additive central nervous system (CNS) depression due to their shared pharmacodynamic effects on GABAergic and sedative pathways. This combination can potentiate sedation, dizziness, ataxia, and respiratory depression, particularly in elderly patients or those with renal impairment. Clinical outcomes may include increased risk of falls, cognitive impairment, and impaired motor coordination, necessitating cautious dose titration."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BACLOFEN vs IPLEX, answered by our medical review team.
BACLOFEN is a Skeletal Muscle Relaxant that works by GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.. IPLEX is a Growth Factor that works by IPLEX (mecasermin rinfabate) is a complex of recombinant human insulin-like growth factor-1 (IGF-1) and its binding protein (IGFBP-3). It activates the IGF-1 receptor, promoting linear growth by stimulating chondrocyte proliferation in epiphyseal growth plates, as well as exerting anabolic effects on muscle and other tissues.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BACLOFEN and IPLEX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BACLOFEN is: Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.. The standard adult dose of IPLEX is: 0.5-2 mg/kg subcutaneously once daily, titrated based on IGF-I levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BACLOFEN and IPLEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BACLOFEN is classified as Category C. First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third t. IPLEX is classified as Category C. IPLEX (mecasermin rinfabate) is a recombinant human insulin-like growth factor-1 (IGF-1) complexed with IGF-binding protein-3. There are no adequate and well-controlled studies in . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.